FDA advisory panel okays renal cell carcinoma drug
Friday, 9 December 2011- The FDA's Oncologic Drugs Advisory Committee voted 13-0 that the FDA should approve the vascular endothelial growth factor receptor inhibitor axitinib (Inlyta) for patients with advanced renal cell carcinoma who haven't responded to another cancer treatment.
The vote came...
Edited by: JV
Treating Chronic Kidney Disease by regeneration of specialised cells
Thursday, 8 December 2011- Damage to podocytes -- a specialised type of epithelial cell in the kidney -- occurs in more than 90 percent of all chronic kidney disease. Now researchers at the Stanford University School of Medicine have uncovered an unexpected pathway that reveals for the first time...
Edited by: JV
PCa prototype diagnostic test shows benefit in reducing repeat biopsies
Wednesday, 7 December 2011- A prototype of a prostate cancer diagnostic test may help urologists distinguish patients who have a true negative biopsy from those who may have occult cancer undetected by prostate biopsy and histopathologic review, new study findings show.
The test, known as...
Edited by; JV
Frequent mutation of genes encoding Ubiquitin-Mediated Proteolysis Pathway components in kidney cancer
Tuesday, 6 December 2011- A study in China revealed that alteration of the ubiquitin-mediated proteolysis pathway (UMPP) may contribute to clear cell renal cell carcinoma (ccRCC ) by activation of the hypoxia regulatory network, providing new clues to trace the key molecular mechanisms and pathways...
Edited by: JV
US team develops blood test to detect membranous nephropathy
Monday, 5 December 2011- Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) has led to the development of a test that can help diagnose membranous nephropathy in its early stages.
The test, which is currently only offered in...
Edited by: JV
More studies needed on suggested link between contraceptive pill and prostate cancer
Friday, 2 December 2011- An international study published in BMJ Open has recently suggested the existence of a casual link between the use of the contraceptive pill and the increase incidence of prostate cancer, due to men’s abnormal exposure to low levels of oestrogen in the environment....
Edited by: JV
Extracorporeal shock wave therapy plus tadalafil in managing patients with Peyronie’s disease
Thursday, 1 December 2011- Extracorporeal shock wave therapy improves erectile function in patients with Peyronie’s disease. However, erectile dysfunction still persists in many cases.
A. Palmieri and colleagues conducted a prospective randomized study to investigate the effects of extracorporeal...
Edited by: JV
Treatment differs in many countries for men with urinary retention due to benign enlarged prostate
Wednesday, 30 November 2011- Men who experience a sudden inability to pass urine because of a non-cancerous enlarged prostate are hospitalised and treated differently depending on where they live, according to an international study published online by the urology journal BJUI.
The paper, which...
Edited by: JV
Sunitinib therapy linked with hyperparathyroidism
Tuesday, 29 November 2011- Almost 70% of patients taking sunitinib (Sutent) as first-line therapy for metastatic renal cell carcinoma developed hyperparathyroidism, Italian researchers report.
The clinical significance is unclear, however.
Sunitinib, a receptor tyrosine kinase (RTK) inhibitor,...
Edited by: JV
Math model could guide advanced prostate cancer treatments
Monday, 28 November 2011- Scientists have designed a first draft of a mathematical model that someday could guide treatment decisions for advanced prostate cancer, in part by helping doctors predict how individual patients will respond to therapy based on the biology of their tumors.
These...
Edited by: JV
